Key Points Citron Research sees Teladoc as a bargain ready to rip higher, citing the end of this government shutdown as a bullish catalyst. While Citron's favorite catalyst seems questionable, Teladoc's bargain valuation might make it worth considering anyway. Teladoc has fallen 66% over three years and trades at just 0.66 times sales despite generating strong free cash flow. 10 stocks we like better than Teladoc Health › Bullish comments from a noted short-seller pushed shares of Teladoc Health ...